Strategies to prevent ischemic heart disease after kidney transplantation

Transplantation Reviews

Volumn 20, Issue 1, 2006, Pages 19-27

  Kasiske, Bertram L ^a,b   Israni, Ajay K ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GLUCOSE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INDAPAMIDE; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RAPAMYCIN; TACROLIMUS; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ANEMIA; ANTIOXIDANT ACTIVITY; BEHAVIOR MODIFICATION; BRADYCARDIA; CLINICAL TRIAL; DIABETES CONTROL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; EDEMA; EVIDENCE BASED MEDICINE; GINGIVA HYPERTROPHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIFESTYLE; PATIENT CARE; PATIENT REFERRAL; PERIOPERATIVE PERIOD; PREOPERATIVE EVALUATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION;

EID: 33645892251     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2006.02.001     Document Type: Review

References (44)

1. Wolfe R.A., Ashby V.B., Milford E.L., Ojo A.O., Ettenger R.E., Agodoa L.Y., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341 23 (1999) 1725-1730
2. Kasiske B.L., Maclean J.R., and Snyder J.J. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol 17 3 (2006) 900-907
3. Kasiske B.L., Cangro C.B., Hariharan S., Hricik D.E., Kerman R.H., Roth D., et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 1 Suppl 2 (2001) 3-95
4. Eagle K.A., Berger P.B., Calkins H., Chaitman B.R., Ewy G.A., Fleischmann K.E., et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 105 10 (2002) 1257-1267
5. McFalls E.O., Ward H.B., Moritz T.E., Goldman S., Krupski W.C., Littooy F., et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 351 27 (2004) 2795-2804
6. Danovitch G.M., Hariharan S., Pirsch J.D., Rush D., Roth D., Ramos E., et al. Management of the waiting list for cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation. J Am Soc Nephrol 13 2 (2002) 528-535
7. Le A., Wilson R., Douek K., Pulliam L., Tolzman D., Norman D., et al. Prospective risk stratification in renal transplant candidates for cardiac death. Am J Kidney Dis 24 1 (1994) 65-71
8. Lewis M.S., Wilson R.A., Walker K., Stegeman-Olsen J., Norman D.J., Barry J.M., et al. Factors in cardiac risk stratification of candidates for renal transplant. J Cardiovasc Risk 6 4 (1999) 251-255
9. Lewis M.S., Wilson R.A., Walker K.W., Wilson D.J., Norman D.J., Barry J.M., et al. Validation of an algorithm for predicting cardiac events in renal transplant candidates. Am J Cardiol 89 7 (2002) 847-850
10. Patel A.D., Abo-Auda W.S., Davis J.M., Zoghbi G.J., Deierhoi M.H., Heo J., et al. Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation. Am J Cardiol 92 2 (2003) 146-151
11. Kasiske B.L., Malik M.A., and Herzog C.A. Risk-stratified screening for ischemic heart disease in kidney transplant candidates. Transplantation 80 6 (2005) 815-820
12. Devereaux P.J., Beattie W.S., Choi P.T., Badner N.H., Guyatt G.H., Villar J.C., et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 331 7512 (2005) 313-321
13. Lindenauer P.K., Pekow P., Wang K., Mamidi D.K., Gutierrez B., and Benjamin E.M. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 353 4 (2005) 349-361
14. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 13 (2005) 1293-1304
15. Burger W., Chemnitius J.M., Kneissl G.D., and Rucker G. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 257 5 (2005) 399-414
16. Grotz W., Siebig S., Olschewski M., Strey C.W., and Peter K. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation 77 12 (2004) 1848-1853
17. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 9438 (2004) 937-952
18. Kasiske B.L., Chakkera H., and Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11 9 (2000) 1735-1743
19. Ducloux D., Bourrinet E., Motte G., and Chalopin J.M. Antiphospholipid antibodies as a risk factor for atherosclerotic events in renal transplant recipients. Kidney Int 64 3 (2003) 1065-1070
20. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 19 (2003) 2560-2572
21. Wang J.-G., and Staessen J.A. Conventional therapy and newer drug classes for cardiovascular protection in hypertension. J Am Soc Nephrol 13 (2002) S208-S215
22. Carlberg B., Sammuelsson O., and Lindholm L.H. Atenolol in hypertension: is it a wise choice?. Lancet 364 9446 (2005) 1684-1689
23. Casas J.P., Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A.D., et al. Effects of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
24. Opelz G., Wujciak T., and Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 53 1 (1998) 217-222
25. Kasiske B.L., Anjum S., Shah R., Skogen J., Kandaswamy C., Danielson B., et al. Hypertension after kidney transplantation. Am J Kidney Dis 43 6 (2004) 1071-1081
26. Mange K.C., Cizman B., Joffe M., and Feldman H.I. Arterial hypertension and renal allograft survival. JAMA 283 5 (2000) 633-638
27. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
28. Studer M., Briel M., Leimenstoll B., Glass T.R., and Bucher H.C. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 165 7 (2005) 725-730
29. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 9500 (2005) 1849-1861
30. Jardine A.G., Fellstrom B., Logan J.O., Cole E., Nyberg G., Gronhagen-Riska C., et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 46 3 (2005) 529-536
31. Holdaas H., Fellstrom B., Jardine A.G., Holme I., Nyberg G., Fauchald P., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 9374 (2003) 2024-2031
32. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant 4 Suppl 7 (2004) 1-53
33. Park S., Barrett-Connor E., Wingard D.L., Shan J., and Edelstein S. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care 19 5 (1996) 450-456
34. De Vegt F., Dekker J.M., Ruhe H.G., Stehouwer C.D., Nijpels G., Bouter L.M., et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42 8 (1999) 926-931
35. Larsen J., Brekke M., Sandvik L., Arnesen H., Hanssen K.F., and Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes 51 8 (2002) 2637-2641
36. The Diabetes Control and Complications Trial and Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 14 (1993) 977-986
37. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 9131 (1998) 837-853
38. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75 14 (1995) 894-903
39. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 25 (2005) 2643-2653
40. Kasiske B.L., Snyder J.J., Gilbertson D., and Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3 2 (2003) 178-185
41. Fellström B., Jardine A.G., Soveri I., Cole E., Neumayer H.H., Maes B., et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 5 8 (2005) 1986-1991
42. Painter P.L., Hector L., Ray K., Lynes L., Paul S.M., Dodd M., et al. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. Am J Kidney Dis 42 2 (2003) 362-369
43. Di Castelnuovo A., Rotondo S., Iacoviello L., Donati M.B., and de Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 105 24 (2002) 2836-2844
44. Miller III E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 1 (2005) 37-46